Charles River Laboratories International, Inc. $CRL Stake Lowered by Engineers Gate Manager LP

Engineers Gate Manager LP cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 68.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,267 shares of the medical research company's stock after selling 64,517 shares during the quarter. Engineers Gate Manager LP owned approximately 0.06% of Charles River Laboratories International worth $6,637,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Empirical Finance LLC boosted its position in Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company's stock valued at $333,000 after purchasing an additional 62 shares during the last quarter. Glenmede Trust Co. NA increased its position in Charles River Laboratories International by 2.8% in the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company's stock worth $467,000 after purchasing an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Charles River Laboratories International by 1.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company's stock worth $1,260,000 after purchasing an additional 80 shares in the last quarter. Syon Capital LLC raised its stake in shares of Charles River Laboratories International by 2.4% during the 2nd quarter. Syon Capital LLC now owns 3,547 shares of the medical research company's stock worth $804,000 after purchasing an additional 83 shares in the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company's stock worth $505,000 after purchasing an additional 83 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 1.8%

Shares of CRL stock opened at $278.02 on Friday. The stock's 50 day simple moving average is $260.17 and its 200 day simple moving average is $205.58. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $303.30. The company has a market capitalization of $13.27 billion, a price-to-earnings ratio of -57.32, a PEG ratio of 2.68 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same quarter in the prior year, the business earned $3.12 earnings per share. The company's revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on CRL. Evercore reissued an "outperform" rating and issued a $320.00 price target on shares of Charles River Laboratories International in a research note on Friday. TD Cowen raised their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, August 10th. CLSA cut shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a research note on Monday, July 20th. Royal Bank Of Canada boosted their target price on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $265.69.

Insider Activity

In other news, CAO Michael Knell sold 6,645 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $260.38, for a total value of $1,730,225.10. Following the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at approximately $3,086,023.76. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Victoria Creamer sold 4,179 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company's stock, valued at $7,788,017.16. This represents a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 165,990 shares of company stock worth $42,606,388. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.